Johnson & Johnson Income from Continuous Operations 2010-2024 | JNJ
Johnson & Johnson annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Johnson & Johnson income from continuous operations for the quarter ending September 30, 2024 was $2.694B, a 37.48% decline year-over-year.
- Johnson & Johnson income from continuous operations for the twelve months ending September 30, 2024 was $14.767B, a 30.79% increase year-over-year.
- Johnson & Johnson annual income from continuous operations for 2023 was $13.326B, a 18.59% decline from 2022.
- Johnson & Johnson annual income from continuous operations for 2022 was $16.37B, a 8.04% decline from 2021.
- Johnson & Johnson annual income from continuous operations for 2021 was $17.801B, a 20.98% increase from 2020.
Johnson & Johnson Annual Income from Continuous Operations (Millions of US $) |
2023 |
$13,326 |
2022 |
$16,370 |
2021 |
$17,801 |
2020 |
$14,714 |
2019 |
$15,119 |
2018 |
$15,297 |
2017 |
$1,300 |
2016 |
$16,540 |
2015 |
$15,409 |
2014 |
$16,323 |
2013 |
$13,831 |
2012 |
$10,514 |
2011 |
$9,672 |
2010 |
$13,334 |
2009 |
$12,266 |
Johnson & Johnson Quarterly Income from Continuous Operations (Millions of US $) |
2024-09-30 |
$2,694 |
2024-06-30 |
$4,686 |
2024-03-31 |
$3,255 |
2023-12-31 |
$4,132 |
2023-09-30 |
$4,309 |
2023-06-30 |
$5,376 |
2023-03-31 |
$-491 |
2022-12-31 |
$2,097 |
2022-09-30 |
$4,310 |
2022-06-30 |
$4,814 |
2022-03-31 |
$5,149 |
2021-12-31 |
$1,659 |
2021-09-30 |
$3,667 |
2021-06-30 |
$6,278 |
2021-03-31 |
$6,197 |
2020-12-31 |
$1,738 |
2020-09-30 |
$3,554 |
2020-06-30 |
$3,626 |
2020-03-31 |
$5,796 |
2019-12-31 |
$4,010 |
2019-09-30 |
$1,753 |
2019-06-30 |
$5,607 |
2019-03-31 |
$3,749 |
2018-12-31 |
$3,042 |
2018-09-30 |
$3,934 |
2018-06-30 |
$3,954 |
2018-03-31 |
$4,367 |
2017-12-31 |
$-10,713 |
2017-09-30 |
$3,764 |
2017-06-30 |
$3,827 |
2017-03-31 |
$4,422 |
2016-12-31 |
$3,814 |
2016-09-30 |
$4,272 |
2016-06-30 |
$3,997 |
2016-03-31 |
$4,457 |
2015-12-31 |
$3,215 |
2015-09-30 |
$3,358 |
2015-06-30 |
$4,516 |
2015-03-31 |
$4,320 |
2014-12-31 |
$2,521 |
2014-09-30 |
$4,749 |
2014-06-30 |
$4,326 |
2014-03-31 |
$4,727 |
2013-12-31 |
$3,519 |
2013-09-30 |
$2,982 |
2013-06-30 |
$3,833 |
2013-03-31 |
$3,497 |
2012-12-31 |
$2,567 |
2012-09-30 |
$2,629 |
2012-06-30 |
$1,408 |
2012-03-31 |
$3,910 |
2011-12-31 |
$218 |
2011-09-30 |
$3,202 |
2011-06-30 |
$2,776 |
2011-03-31 |
$3,476 |
2010-12-31 |
$1,942 |
2010-09-30 |
$3,417 |
2010-06-30 |
$3,449 |
2010-03-31 |
$4,526 |
2009-12-31 |
$2,206 |
2009-09-30 |
$3,345 |
2009-06-30 |
$3,208 |
2009-03-31 |
$3,507 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$374.313B |
$85.159B |
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|